<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352310</url>
  </required_header>
  <id_info>
    <org_study_id>UCB-HIEA-01</org_study_id>
    <nct_id>NCT03352310</nct_id>
  </id_info>
  <brief_title>Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia</brief_title>
  <official_title>Umbilical Cord Blood Mononuclear Cell Bank in Hong Kong and Treatment of Neonatal Cerebral Ischemia and Anemia - Part IV Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mononuclear Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Spinal Cord Injury Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mononuclear Therapeutics Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to investigate the feasibility and safety of autologous umbilical cord blood
      transfusion to treat the newborn infants with presence of clinical indications of neonatal
      hypoxic-ischemia encephalopathy (HIE) and anemia. Umbilical cord blood (UCB) is collected
      following labor and is transfused intravenously within 48 hours after the birth. Newborn
      infant without UCB available recieves the standard care will be enrolled as control group.

      Following the autologous UCB transfusion in the study group or standard care in the control
      group, HIE subjects will be followed for 2 years for survival and neurodevelopmental outcomes
      and anemia subjects will be followed for 6 months to assess the survival and change of
      hematocrit and hemoglobin levels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study Group - autologous umbilcial cord blood transfusion
Control Group - standard care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIE: Mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Mortality Rate of the HIE Subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anemia: Change from Baseline Hematocrit</measure>
    <time_frame>48 hours, 1 week, 3 months, 6 months</time_frame>
    <description>Change from Baseline Hematocrit of the Anemia Subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIE: HINE</measure>
    <time_frame>6 months, 1 year and 2 years</time_frame>
    <description>Hammersmith Infant Neurological Examination (HINE) of the HIE Subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIE: HNNE</measure>
    <time_frame>-1 day, 3 months (before discharge)</time_frame>
    <description>Hammersmith Neonatal Neurological Examination (HNNE) of the HIE Subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIE: GMDS</measure>
    <time_frame>6 months, 1 year and 2 years</time_frame>
    <description>Griffiths Mental Development Scale (GMDS) of the HIE Subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIE: CBCL</measure>
    <time_frame>2 years</time_frame>
    <description>Child Behavior Checklist for Attention Deficit of the HIE Subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIE: Q-CHAT</measure>
    <time_frame>2 years</time_frame>
    <description>Quantitative Checklist for Autism in Toddlers of the HIE Subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia: hemoglobin</measure>
    <time_frame>48 hours, 1 week, 3 months and 6 months</time_frame>
    <description>Change from Baseline hemoglobin of the Anemia Subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia: Oxygenation level</measure>
    <time_frame>48 hours, 1 week</time_frame>
    <description>Change from Baseline SpO2 of the Anemia Subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia: Oxidative Stress Level</measure>
    <time_frame>48 hours, 1 week, 3 months, and 6 months</time_frame>
    <description>Change of Baseline Isoprostane of the Anemia Subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia: Requirements of Packed Cell Transfusion</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of Requirements of Packed Cell Transfusion by the Anemia Subjects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Event</measure>
    <time_frame>2 years</time_frame>
    <description>Safety outcomes are Incidence of Adverse Events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypoxic-Ischemic Encephalopathy</condition>
  <condition>Hypoxia Neonatal</condition>
  <condition>Cerebral Ischemia of Newborn</condition>
  <condition>Anemia, Neonatal</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous UCB transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous umbilical cord blood (UCB)</intervention_name>
    <description>autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>standard care procedure to the newborn infants presence of HIE and/or anemia</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  evidence of asphyxiation, defined by 5-minute Apgar score ≤ 5;

          -  evidence of HIE, defined by UCB pH &lt;7.15 or base excess ≤ 10mM;

          -  subjects with HIE confirmed by clinical features and initial investigations;

          -  subjects with evidence of anemia, defined by hematocrit &lt; 40% or hemoglobin ≤ 13g/dL
             within the first 96 hours of life;

          -  obtain the informed consent from parents

        Exclusion Criteria:

          -  congestive cardiac failure;

          -  microcephaly, anencephaly, encephalocele, or other abnormality

          -  conjoint twins;

          -  chromosomal disorders

          -  fetal alcohol syndrome

          -  spinal bifida or other neural tube defects

          -  subjects have other neurological deficit conditions

          -  polycythemia

          -  congenital hematological malignancy

          -  investigator decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Lam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Lam, MD</last_name>
    <phone>+852 35052851</phone>
    <email>hshslam@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronald Wang, MD</last_name>
    <phone>+852 35052810</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Lam, M.D.</last_name>
      <phone>+852 35052851</phone>
    </contact>
    <investigator>
      <last_name>Simon Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi Kong Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Fung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>umbilical cord blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Neonatal</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

